Abiopharma

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment

InMed Announces Results of 2025 Annual General and Special Meeting

Johnson & Johnson - U.S. FDA Approval of RYBREVANTFASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)

U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)

ResMed Inc. Daily Stock Update

UTHR: Notification

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of VYNE Therapeutics Inc. (NASDAQ: VYNE)

NervGen Pharma Announces Filing of Form F-10 Registration Statement with the SEC under MJDS

Xcelerate Issues Year-End Update on Strategic Focus and 2026 Plans

Voting Rights and Shares Capital of the Company